GSK将收购其蛋白质组学合作伙伴Cellzome的全部控制权

Pharmadeals Review Pub Date : 2012-05-21 DOI:10.3833/PDR.V2012I5.1743

Heather Cartwright

{"title":"GSK将收购其蛋白质组学合作伙伴Cellzome的全部控制权","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I5.1743","DOIUrl":null,"url":null,"abstract":"GlaxoSmithKline (GSK) has agreed to acquire the 80.02% of its proteomics research partner Cellzome that it does not already own for £61 M (US$98 M) in cash. The acquisition will expand GSK’s existing drug discovery platform and add to its capacity to characterise drug targets. Simultaneously, the two parties intend to create a spin-off company, which would hold the rights to certain Cellzome assets and activities that GSK does not wish to progress.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"GSK to Acquire Full Control of its Proteomics Partner Cellzome\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I5.1743\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"GlaxoSmithKline (GSK) has agreed to acquire the 80.02% of its proteomics research partner Cellzome that it does not already own for £61 M (US$98 M) in cash. The acquisition will expand GSK’s existing drug discovery platform and add to its capacity to characterise drug targets. Simultaneously, the two parties intend to create a spin-off company, which would hold the rights to certain Cellzome assets and activities that GSK does not wish to progress.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I5.1743\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I5.1743","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

葛兰素史克(GSK)已同意以6100万英镑(9800万美元)现金收购其蛋白质组学研究合作伙伴Cellzome尚未拥有的80.02%股份。此次收购将扩大GSK现有的药物发现平台，并增加其表征药物靶点的能力。同时，双方打算创建一家分拆公司，该公司将持有GSK不希望推进的某些Cellzome资产和活动的权利。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

GSK to Acquire Full Control of its Proteomics Partner Cellzome

GlaxoSmithKline (GSK) has agreed to acquire the 80.02% of its proteomics research partner Cellzome that it does not already own for £61 M (US$98 M) in cash. The acquisition will expand GSK’s existing drug discovery platform and add to its capacity to characterise drug targets. Simultaneously, the two parties intend to create a spin-off company, which would hold the rights to certain Cellzome assets and activities that GSK does not wish to progress.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量